Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma

Chai Discovery, a biotech firm leveraging AI to predict molecular interactions, secured a whopping $400 million in Series C funding, boosting its valuation to a staggering $3.8 billion. This influx, led by Index Ventures and supported by Kleiner Perkins, Sequoia Capital, and Dimension, underscores the growing trust in AI-driven drug discovery. The company's AI-designed antibodies are now attracting significant interest from major pharmaceutical companies, hinting at a transformative shift in how biotech firms approach drug development and potentially revolutionizing the industry's R&D landscape.